310 related articles for article (PubMed ID: 31514420)
1. Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis.
Cline A; Bartos GJ; Strowd LC; Feldman SR
Children (Basel); 2019 Sep; 6(9):. PubMed ID: 31514420
[No Abstract] [Full Text] [Related]
2. Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis-A Review.
Cline A; Berg A; Bartos GJ; Strowd LC; Feldman SR
J Clin Aesthet Dermatol; 2020 Jun; 13(6 Suppl):S33-S38. PubMed ID: 33282108
[No Abstract] [Full Text] [Related]
3. Topical and Oral Therapies for Childhood Atopic Dermatitis and Plaque Psoriasis.
Frantz T; Wright EG; Balogh EA; Cline A; Adler-Neal AL; Feldman SR
Children (Basel); 2019 Nov; 6(11):. PubMed ID: 31694234
[TBL] [Abstract][Full Text] [Related]
4. Reappraising the Use of Systemic Immunomodulators for Psoriasis and Eczema in the Military.
Russell A; Williamson S; Rosenberg A; Cho S
Mil Med; 2024 Apr; ():. PubMed ID: 38607726
[TBL] [Abstract][Full Text] [Related]
5. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases.
Kaufman BP; Alexis AF
Curr Allergy Asthma Rep; 2018 Aug; 18(10):55. PubMed ID: 30171358
[TBL] [Abstract][Full Text] [Related]
6. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
7. Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review.
Igelman S; Kurta AO; Sheikh U; McWilliams A; Armbrecht E; Jackson Cullison SR; Kress DW; Smith A; Castelo-Soccio L; Treat J; Boothe WD; Diaz LZ; Levy ML; Patel A; Lee LW; Fraile-Alonso MC; Antaya RJ; Shah S; Kittler N; Arkin L; Siegfried E
J Am Acad Dermatol; 2020 Feb; 82(2):407-411. PubMed ID: 31606479
[TBL] [Abstract][Full Text] [Related]
8. FDA Approved Biologics: Can Etanercept and Ustekinumab be Considered a First-Line Systemic Therapy for Pediatric/Adolescents in Moderate to Severe Psoriasis? A Systematic Review.
Aslam N; Saleem H; Murtazaliev S; Quazi SJ; Khan S
Cureus; 2020 Aug; 12(8):e9812. PubMed ID: 32953323
[TBL] [Abstract][Full Text] [Related]
9. Long-term off-label dupilumab in pediatric atopic dermatitis: A case series.
Treister AD; Lio PA
Pediatr Dermatol; 2019 Jan; 36(1):85-88. PubMed ID: 30338546
[TBL] [Abstract][Full Text] [Related]
10. [Status quo and prospects for systemic therapy of atopic dermatitis. Biologics ante portas].
Biedermann T; Werfel T
Hautarzt; 2015 Feb; 66(2):108-13. PubMed ID: 25645542
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severe psoriasis in children: recommendations of an Italian expert group.
Fortina AB; Bardazzi F; Berti S; Carnevale C; Di Lernia V; El Hachem M; Neri I; Gelmetti CM; Lora V; Mazzatenta C; Milioto M; Moretta G; Patrizi A; Peris K; Villani A
Eur J Pediatr; 2017 Oct; 176(10):1339-1354. PubMed ID: 28836064
[TBL] [Abstract][Full Text] [Related]
12. Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital.
Sanz-Gil R; Pellicer A; Montesinos MC; Valcuende-Cavero F
J Dermatolog Treat; 2020 Jun; 31(4):370-377. PubMed ID: 30924390
[No Abstract] [Full Text] [Related]
13. Comparative efficacy of biologics in psoriasis: a review.
Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
[TBL] [Abstract][Full Text] [Related]
14. Biologics in atopic dermatitis.
Chan S
Curr Opin Allergy Clin Immunol; 2021 Jun; 21(3):297-302. PubMed ID: 33871424
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
[TBL] [Abstract][Full Text] [Related]
16. Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.
van Bezooijen JS; van Doorn MBA; Schreurs MWJ; Koch BCP; Te Velthuis H; Prens EP; van Gelder T
Ther Drug Monit; 2017 Aug; 39(4):379-386. PubMed ID: 28570371
[TBL] [Abstract][Full Text] [Related]
17. Atopic dermatitis 2017: where we were 10-15 years ago in psoriasis.
No DJ; Amin M; Egeberg A; Thyssen JP; Wu JJ
J Dermatolog Treat; 2018 Feb; 29(1):100-101. PubMed ID: 28604121
[TBL] [Abstract][Full Text] [Related]
18. Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
Zhang M; Carter C; Olson WH; Johnson MP; Brennem SK; Lee S; Farahi K
J Drugs Dermatol; 2017 Mar; 16(3):220-226. PubMed ID: 28301617
[TBL] [Abstract][Full Text] [Related]
19. Response to Biologic Therapy in Skin of Colour Participants With Moderate-to-Severe Psoriasis and Atopic Dermatitis: A Systematic Review.
Rijal H; Bouadi N; Abduelmula A; Maliyar K; Bourkas AN; Georgakopoulos JR; Yeung J
J Cutan Med Surg; 2024 Jun; ():12034754241260023. PubMed ID: 38847375
[TBL] [Abstract][Full Text] [Related]
20. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
